Enterprise Value

4.048B

Cash

713.7M

Avg Qtr Burn

N/A

Short % of Float

7.72%

Insider Ownership

2.53%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PYLARIFY Details
Prostate cancer, Cancer

Approved

Quarterly sales

DEFINITY® Room Temperature Details
Suboptimal echocardiograms

Approved

Quarterly sales

AZEDRA® (iobenguane I 131) Details
Pheochromocytoma , Paraganglioma , Solid tumor/s

Approved

Quarterly sales

RELISTOR Details
Constipation

Approved

Quarterly sales

Flurpiridaz F 18 Details
Heart disease, Coronary artery disease

NDA

Acceptance for review

¹⁷⁷Lu-PNT2002 Details
Cancer, Castration-resistant prostate cancer

Phase 3

Data readout

Phase 2

Data readout

LNTH-1404 Details
Prostate cancer, Cancer

Failed

Discontinued